Physician profile
Ryan Cho
NPI 1477070670
$3,996.55
in general payments reported to CMS, 2019-2025
17 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,717 · 2022: $730 · 2023: $43.40 · 2024: $373 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $946.08 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $684.84 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $439.18 | 2024-2025 | |
| Abbvie INC. | $426.98 | 2021-2024 | |
| Novo Nordisk INC | $367.20 | 2021-2025 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $344.47 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $175.84 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $172.46 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.91 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $116.84 | 2022 | |
| Amgen INC. | $61.74 | 2024-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $38.17 | 2024 | |
| Janssen Biotech, INC. | $30.08 | 2022 | |
| Abbott Laboratories | $18.93 | 2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $15.25 | 2025 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $14.19 | 2021 | |
| Glaxosmithkline, LLC. | $12.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.